Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Cancer Biother Radiopharm ; 22(2): 243-9, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17600471

RESUMO

Accurate measurements of whole-body activity retention of patients during radionuclide therapy are essential for two reasons: First, they enable the correct radiation protection advice to be given and second, they permit the accurate determination of the absorbed whole-body dose delivered during therapy. This, in turn, allows treatment planning to be carried out for future radionuclide therapy on an individual patient basis, and also enables the investigation of the potential correlation of absorbed dose with treatment outcome in groups of patients. There are significant difficulties associated with taking whole-body retention measurements of children, especially when they are very young and/or unwell. It is essential to carry these out in a way that minimises disturbance to the child while still providing good quality data. To accomplish this, we have aimed to optimize the following aspects of the procedure: (i) the environment in which the measurements are performed; (ii) the equipment--which includes the recent installation of a specially designed whole-body activity monitoring system for these patients; and (iii) the methodology for calculating the absorbed dose. These improvements have allowed large numbers of accurate and reproducible whole-body measurements to be collected following patient administrations. This has enabled the identification of more phases of radionuclide excretion during therapy than had previously been observed. These data have been used for radiation protection advice and treatment planning. Two (2) patients were given multiple radionuclide treatments and we were able to compare the whole-body doses delivered.


Assuntos
Dosagem Radioterapêutica/normas , Contagem Corporal Total/instrumentação , Contagem Corporal Total/métodos , 3-Iodobenzilguanidina/química , 3-Iodobenzilguanidina/farmacocinética , 3-Iodobenzilguanidina/uso terapêutico , Criança , Humanos , Radioisótopos do Iodo/química , Contagem Corporal Total/normas
2.
Nucl Med Commun ; 26(9): 839-41, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16096589

RESUMO

Administration of a radiopharmaceutical may result in a radiation dose to an infant due to ingestion of the radiopharmaceutical secreted in the breast milk. Following a maternal administration of Co labelled to vitamin B12 (cyanocobalamin) as part of a Schilling test an estimate of the absorbed dose to a breast feeding infant was calculated. Milk samples were collected from every feed in the first 24 h, and at approximately 48 and 72 h post-administration. The absorbed dose to the infant's liver (the organ receiving the highest dose) was calculated to be 0.23 mGy. The effective dose to the infant was calculated to be 0.025 mSv, which is considerably lower than the current regulatory limit of 1 mSv. The Administration of Radioactive Substances Advisory Committee advise that the first feed, at approximately 4 h after administration, be discarded. The data show that this was unwarranted, and that the peak concentration of Co in the breast milk occurred at around 24 h.


Assuntos
Radioisótopos de Cobalto/análise , Leite Humano/química , Radiometria/métodos , Medição de Risco/métodos , Teste de Schilling/métodos , Vitamina B 12 , Aleitamento Materno/efeitos adversos , Radioisótopos de Cobalto/efeitos adversos , Feminino , Humanos , Recém-Nascido , Doses de Radiação , Lesões por Radiação/etiologia , Lesões por Radiação/prevenção & controle , Fatores de Risco , Teste de Schilling/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA